If having high FGF-21 levels benefit mitochondrial patients, the FGF-21 analogue that has been trialled as a drug treatment for hyperglycaemia and obesity [41,42] would also have potential as a therapy for MD. The gene discussed is FGF21; the disease is obesity due to melanocortin 4 receptor deficiency.